BioVaxys Technology Corp. has entered into an agreement with MilliporeSigma, a global contract development and manufacturing organization (CDMO), to manufacture a supply of GLP-grade BVX-1021, the company’s newly developed vaccine (BVX-1021) for the strain of coronavirus that causes Severe Acute Respiratory Syndrome (SARS1), the respiratory illness responsible for the deadly 2002–2004 pandemic. There are no vaccines approved for SARS1. BVX-1021 is the subject of an ongoing research coll...